Sheri Booten

4.4k total citations · 2 hit papers
29 papers, 3.4k citations indexed

About

Sheri Booten is a scholar working on Molecular Biology, Genetics and Epidemiology. According to data from OpenAlex, Sheri Booten has authored 29 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 8 papers in Genetics and 5 papers in Epidemiology. Recurrent topics in Sheri Booten's work include Iron Metabolism and Disorders (5 papers), Hemoglobinopathies and Related Disorders (5 papers) and Liver Disease Diagnosis and Treatment (4 papers). Sheri Booten is often cited by papers focused on Iron Metabolism and Disorders (5 papers), Hemoglobinopathies and Related Disorders (5 papers) and Liver Disease Diagnosis and Treatment (4 papers). Sheri Booten collaborates with scholars based in United States, Sweden and Norway. Sheri Booten's co-authors include Brett P. Monia, Sanjay Bhanot, Mark J. Graham, Robert A. McKay, Sanjay K. Pandey, Susan Murray, Susan M. Freier, Lynnetta M. Watts, C. Frank Bennett and Christine Esau and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Sheri Booten

27 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting

2006 1.7k citations Christine Esau, Scott Davis et al. Cell Metabolism profile →
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennaryN-acetyl galactosamine improves potency 10-fold in mice

2014 468 citations Mark J. Graham, Chenguang Zhao et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sheri Booten United States	17	2.3k	1.5k	493	307	266	29	3.4k
Marie C. Lin China	34	2.5k 1.1×	1.8k 1.2×	277 0.6×	110 0.4×	170 0.6×	56	3.7k
Ryan J.O. Dowling Canada	19	3.9k 1.7×	1.1k 0.7×	345 0.7×	144 0.5×	302 1.1×	29	4.8k
Cong Yan United States	30	1.4k 0.6×	502 0.3×	440 0.9×	129 0.4×	296 1.1×	69	3.2k
Hong Du United States	38	1.9k 0.8×	609 0.4×	691 1.4×	118 0.4×	892 3.4×	104	4.4k
Jessica L. Yecies United States	10	2.0k 0.8×	926 0.6×	468 0.9×	70 0.2×	333 1.3×	13	3.0k
Ángeles Durán United States	29	2.5k 1.1×	1.0k 0.7×	1.4k 2.8×	83 0.3×	254 1.0×	38	3.9k
Rui-Hong Wang United States	15	1.6k 0.7×	341 0.2×	869 1.8×	358 1.2×	590 2.2×	16	3.4k
Olivier Coqueret France	31	2.1k 0.9×	565 0.4×	171 0.3×	120 0.4×	312 1.2×	69	3.4k
Guido T. Bommer Belgium	33	3.0k 1.3×	2.0k 1.3×	301 0.6×	67 0.2×	301 1.1×	60	4.2k
Jer-Yen Yang United States	17	2.7k 1.2×	932 0.6×	175 0.4×	96 0.3×	131 0.5×	20	3.4k

Countries citing papers authored by Sheri Booten

Since Specialization

Citations

This map shows the geographic impact of Sheri Booten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sheri Booten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sheri Booten more than expected).

Fields of papers citing papers by Sheri Booten

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sheri Booten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sheri Booten. The network helps show where Sheri Booten may publish in the future.

Co-authorship network of co-authors of Sheri Booten

This figure shows the co-authorship network connecting the top 25 collaborators of Sheri Booten. A scholar is included among the top collaborators of Sheri Booten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sheri Booten. Sheri Booten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cansby, Emmelie, Jingjing Zhang, Sheri Booten, et al.. (2025). Inhibition of GCKIII kinases STK25 and MST3 mitigates organ lipotoxicity and enhances metabolic resilience under nutritional stress. BMC Medicine. 23(1). 518–518.

Yang, Ya‐Wen, Bibek Poudel, Poonam Dhillon, et al.. (2022). Antisense oligonucleotides ameliorate kidney dysfunction in podocyte-specific APOL1 risk variant mice. Molecular Therapy. 30(7). 2491–2504. 11 indexed citations

Kurhe, Yeshwant, Sima Kumari, Emmelie Cansby, et al.. (2021). Silencing of STE20‐type kinase MST3 in mice with antisense oligonucleotide treatment ameliorates diet‐induced nonalcoholic fatty liver disease. The FASEB Journal. 35(5). e21567–e21567. 22 indexed citations

Viney, Nicholas J., Shuling Guo, Bruce L. Tai, et al.. (2020). Ligand Conjugated Antisense Oligonucleotide for the Treatment of Transthyretin Amyloidosis: Preclinical and Phase 1 Data. ESC Heart Failure. 8(1). 652–661. 65 indexed citations

Aghajan, Mariam, Sheri Booten, Magnus Althage, et al.. (2019). Antisense oligonucleotide treatment ameliorates IFN-γ–induced proteinuria in APOL1-transgenic mice. JCI Insight. 4(12). 69 indexed citations

Cansby, Emmelie, Esther Nuñez‐Durán, Manoj Amrutkar, et al.. (2018). Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease. Cellular and Molecular Gastroenterology and Hepatology. 7(3). 597–618. 37 indexed citations

Tasfaout, Hichem, Shuling Guo, Christine Kretz, et al.. (2017). Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice. Nature Communications. 8(1). 15661–15661. 72 indexed citations

Posey, Karen L., Françoise Coustry, Alka C. Veerisetty, et al.. (2017). Antisense Reduction of Mutant COMP Reduces Growth Plate Chondrocyte Pathology. Molecular Therapy. 25(3). 705–714. 12 indexed citations

Ackermann, Elizabeth J., Shuling Guo, Merrill D. Benson, et al.. (2016). Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides. Amyloid. 23(3). 148–157. 114 indexed citations

10.

Aghajan, Mariam, Carla Casu, Sheri Booten, et al.. (2016). Developing a Galnac-Conjugated TMPRSS6 Antisense Therapy for the Treatment of β-Thalassemia. Blood. 128(22). 1013–1013. 5 indexed citations

11.

Huang, Lulu, Sagar Damle, Sheri Booten, et al.. (2015). Partial Hepatectomy Induced Long Noncoding RNA Inhibits Hepatocyte Proliferation during Liver Regeneration. PLoS ONE. 10(7). e0132798–e0132798. 26 indexed citations

12.

Guo, Shuling, Mariam Aghajan, Carla Casu, et al.. (2015). Targeting TMPRSS6 Using Antisense Technology for the Treatment of Beta-Thalassemia. Blood. 126(23). 753–753. 2 indexed citations

13.

Guo, Shuling, Sheri Booten, Mariam Aghajan, et al.. (2013). Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin–related liver disease in mice. Journal of Clinical Investigation. 124(1). 251–261. 55 indexed citations

14.

Guo, Shuling, Carla Casu, Sara Gardenghi, et al.. (2013). Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice. Journal of Clinical Investigation. 123(4). 1531–1541. 184 indexed citations

15.

Lee, Richard, Wuxia Fu, Mark J. Graham, et al.. (2012). Comparison of the pharmacological profiles of murine antisense oligonucleotides targeting apolipoprotein B and microsomal triglyceride transfer protein. Journal of Lipid Research. 54(3). 602–614. 31 indexed citations

16.

Yu, Xing, Susan F. Murray, Lynnetta M. Watts, et al.. (2008). Reduction of JNK1 expression with antisense oligonucleotide improves adiposity in obese mice. American Journal of Physiology-Endocrinology and Metabolism. 295(2). E436–E445. 27 indexed citations

17.

Yu, Xing, Sanjay K. Pandey, Sheri Booten, et al.. (2008). Reduced adiposity and improved insulin sensitivity in obese mice with antisense suppression of 4E-BP2 expression. American Journal of Physiology-Endocrinology and Metabolism. 294(3). E530–E539. 15 indexed citations

18.

Sloop, Kyle W., Aaron D. Showalter, Amy L. Cox, et al.. (2007). Specific Reduction of Hepatic Glucose 6-Phosphate Transporter-1 Ameliorates Diabetes while Avoiding Complications of Glycogen Storage Disease. Journal of Biological Chemistry. 282(26). 19113–19121. 10 indexed citations

19.

Esau, Christine, Scott Davis, Susan Murray, et al.. (2006). miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metabolism. 3(2). 87–98. 1717 indexed citations breakdown →

20.

Yu, Xing, Susan F. Murray, Sanjay K. Pandey, et al.. (2005). Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice†. Hepatology. 42(2). 362–371. 231 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact